SavedAdd your journal

Journals / Yeni Tıp Dergisi / 2013 / Cilt: 30 - Sayı: 2

Akut koroner sendromlu hastalarda kötü prognoz göstergesi olarak azalmıştır Hepsidin-25 Düzeyi

Decreased hepcidin-25 level as a predictor of poor prognosis in acute coronary syndrome patients

Tolga ÇİMEN
Ekrem YETER
Mehmet DOĞAN
Murat AKÇAY
HÜSEYİN AYHAN
Telat KELEŞ
Tahir DURMAZ
Nihal Akar BAYRAM
Engin BOZKURT
Pages
115–120
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The peptide hormone hepcidin-25 is known as a type-II acute phase protein in patients with chronic inflammatory conditions and it has a central role in iron homeostasis as well as in anemia, inflammation and hypoxia.
📊
Key Findings & Data:Herein, we evaluated whether hepcidin-25 level has a prognostic role in patients with acute coronary syndromes (ACS).
💡
Conclusion & Impact:Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: The peptide hormone hepcidin-25 is known as a type-II acute phase protein in patients with chronic inflammatory conditions and it has a central role in iron homeostasis as well as in anemia, inflammation and hypoxia. Atherosclerosis is widely accepted as a chronic inflammatory disease. Herein, we evaluated whether hepcidin-25 level has a prognostic role in patients with acute coronary syndromes (ACS). Material and Method: Forty-eight patients with ACS admitted to the coronary care unit of our hospital were included in Group 1, 19 patients without any significant coronary artery disease were included in Group 2 and 20 healthy subjects as control were included in Group 3. Serum hepcidin-25 levels were measured with Hepcidin ELISA kits. Results: Patients with ACS were followed-up for up to 24 months after admission with regard to cardiac events including death, myocardial infarction and revascularisa- tion. There was no significant difference between the baseline biochemical and clinical characteristics of Group 1 and Group 2. Hepcidin-25 level was lower in Group 1 when compared with other Groups (192± 74 ng/mL, 296 ±104 ng/mL, 303.8±92.1, p<0.01). Hepcidin-25 level was found significantly lower in patients who developed a cardiac event compared to those who did not (140 ± 78 ng/ml vs 208±74 ng/ml, p<0.05) but ferritin and hsCRP were similar. Conclusions . Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.

🔖

Cite This Article

ÇİMEN, T., YETER, E., DOĞAN, M., AKÇAY, M., AYHAN, H., KELEŞ, T., DURMAZ, T., BAYRAM, N. A., BOZKURT, E. (2013). Akut koroner sendromlu hastalarda kötü prognoz göstergesi olarak azalmıştır Hepsidin-25 Düzeyi. Yeni Tıp Dergisi, Cilt: 30 - Sayı: 2, 115–120. https://ajindex.com/articles/338205

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ramakrishna G, Rooke TW, Cooper LT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med 2003;8(3):203-10
  2. Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, et al. HFE mutation and dietary iron content interact to increase ischemia/ reperfusion injury of the heart in mice. Circ Res 2003;92(11):1240-6
  3. Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 2004;109(15):1877-85
  4. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz- Knappe P, et al. LEAP-1, a novel highly disulfide-bounded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480(2-3):147-50
  5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276(11): 7806-10
  6. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110(7):1037-44
  7. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276(11):7811-9
  8. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306(5704):2090-3
  9. Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A 2004;101(25):9263-5
  10. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute- phase protein. Blood 2003;101(7):2461-3
  11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783-8
  12. Suzuki H, Toba K, Kato K, Ozawa T, Tomosugi N, Higuchi M, et al. Serum hepcidin-20 is elevated during the acute phase of myocardial infarction. Tohoku J Exp Med 2009;218(2):93-8
  13. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST- elevation myocardial infarcti